Multiple Myeloma

More Evidence Firefighters Risk Cancer From 9/11 Exposure

(NBCNews.com) Apr 26, 2018 - Firefighters who worked the site of the 9/11 attacks on the World Trade Center in New York have an extra-high risk of cancer, especially multiple myeloma, researchers reported Thursday.

read article

Blood Cancer Precursor Found in 9/11 Firefighters

(Albert Einstein College Of Medicine) Apr 26, 2018 - A study in today's issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead to the blood cancer multiple myeloma.

read press release

Karyopharm to Pursue FDA Approval For Multiple Myeloma Drug Based On New Study Results

(STAT) Apr 30, 2018 - A typically reliable method of securing U.S. approval for a cancer drug these days is to run a small, single-arm clinical trial in patients no longer responsive to all approved therapies. Eke out a modest benefit for patients from the study, and FDA is often willing to greenlight approval.

read article

Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma

(Karyopharm) April 30, 2018 - Oral selinexor achieves 25.4% overall response rate and median duration of response of 4.4 months in patients with penta-refractory myeloma; company plans to submit a New Drug Application to the FDA in the second half of 2018.

read corporate press release

In Multiple Myeloma, Different Types Of Blood Biopsies Match Up Well With Bone Marrow Tests

(Dana Farber) Apr 27, 2018 - Bone marrow biopsies are the gold standard for diagnosing and monitoring the progression of multiple myeloma, but these procedures are far too invasive to perform at every patient visit.

read press release

Op-Ed: The Problem With Miracle Cancer Cures

(New York Times) Apr 19, 2018 - The promise of new treatments like immunotherapies have blurred the line between cure and comfort — and between hope and hopelessness — disrupting the fragile equilibrium that we doctors have long taken for granted.

read article

Stand Up To Cancer Takes New Approach to Multiple Myeloma, Focusing on Precursor Conditions

(AACR 2018) Apr 15, 2018 - Stand Up To Cancer announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma, an incurable blood cancer of plasma cells, through early detection of precursor conditions before they turn into full-blown disease.

read press release

Cancer Wrap: Blueprint, Checkmate, More AACR News & Phase 3 Blues

(Xconomy National) Apr 18, 2018 - The big headlines from the American Association for Cancer Research meeting in Chicago were all about the battle over the latest lung cancer data, and for good reason. Lung cancer remains the deadliest cancer, but the Phase 3 data suggest that treatment options for some of the direst cases could soon rapidly expand.

read article

Chip-Based Blood Test For Multiple Myeloma Could Make Bone Biopsies A Relic Of The Past

(University of Kansas) Apr 19, 2018 - The days of using bone biopsies to guide treatment for multiple myeloma and other cancers, such as many types of leukemia, may be numbered.

read press release

Darzalex Combo Wins Nod For Newly Diagnosed Multiple Myeloma

(PharmaTimes [UK]) May 8, 2018 - Janssen/Genmab's Darzalex has become the first monoclonal antibody to be approved in the US to treat patients newly diagnosed with multiple myeloma.

read article

Janssen Announces Darzalex (Daratumumab) U.S. FDA Approval For Newly Diagnosed Patients With Multiple Myeloma Who Are Transplant Ineligible

(The Myeloma Beacon) May 7, 2018 - The Janssen Pharmaceutical Companies of Johnson & Johnson an­nounced today that the U.S. Food and Drug Administration (FDA) has approved DARZALEX® (dara­tu­mu­mab) in combi­na­tion with VELCADE® (bor­tez­o­mib)*, a pro­teasome inhibitor (PI); mel­phalan, an alkylat­ing agent; and pred­ni­sone – VMP – for the treatment of patients with newly diag­nosed multiple myeloma who are ineligible for autol­o­gous stem cell transplant (ASCT).

read article

bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

(bluebird bio) May 16, 2018 - bluebird bio, Inc. announced that updated interim data from CRB-401, its Phase 1 study of bb2121, an anti-BCMA CAR T cell therapy being developed by the company and Celgene, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

read corporate press release

Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings

(Boston Business Journals) May 17, 2018 - Data being presented underscore commitment to improving patient outcomes and care; six Takeda Oncology-sponsored abstracts accepted for presentation at ASCO 2018 and eight abstracts accepted for presentation at EHA 2018.

read article

Janssen to Present New Data in Urothelial, Hematologic and Prostate Cancers at ASCO 2018, Including Best of ASCO Selections

(Janssen) May 16, 2018 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced 21 company-sponsored abstracts will be presented at the 2018 ASCO Annual Meeting in Chicago, IL on June 1-5. New data analyses in support of a portfolio of products, including the investigational treatment erdafitinib, IMBRUVICA® (ibrutinib), DARZALEX® (daratumumab), ERLEADA™ (apalutamide) and ZYTIGA® (abiraterone acetate), will be highlighted across urothelial, hematologic and prostate cancers.

read corporate press release

GRAIL to Present New Data from Circulating Cell-free Genome Atlas (CCGA) Study at 2018 American Society of Clinical Oncology Annual Meeting

(Morningstar) May 16, 2018 - Results show prototype assays detected high mortality cancer types at early stages.

read article

Internationally Recognized Scientist is the New Chief of Myeloma at Roswell Park

(RPCI) May 15, 2018 - Jens Hillengass, MD, is a clinician and researcher focusing on ways to improve patients’ quality of life.

read press release

Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

(NASDAQ) May 9, 2018 - Cellectar Biosciences today announces that the U.S. Food and Drug Administration(FDA) Office of Orphan Products Development has granted Orphan Drug Designation to CLR 131, the company's lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of rhabdomyosarcoma, a rare pediatric cancer.

read article

UAB Recruiting For Clinical Trial To Determine Therapies For Eradication Of Multiple Myeloma

(UAB) May 9, 2018 - Multiple myeloma is the second most common type of blood cancer in the United States, impacting more than 25,000 people each year and disproportionatly affecting African-American men.

read article

ASCO’s TAPUR Study Website Now Features Updates on Patient Cohort Expansions and Closures

(ASCO in Action) May 14, 2018 - ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study now provides a full list of patient cohort expansions and closures on its website.

read article

Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018

(BMS) May 16, 2018 - First analysis from Phase 3 CheckMate -227 Part 1b in first-line non-small cell lung cancer, assessing Opdivo plus chemotherapy and Opdivo plus Yervoy versus chemotherapy in patients with PD-L1 <1%; Updated data from Phase 3 CheckMate -238 study of Opdivo as adjuvant treatment in Stage III/IV melanoma will further explore potential durability of recurrence-free survival; Seven BMS compounds to be featured in presentations spanning more than 20 types of cancer.

read corporate press release
Next Page